MULTIPLE MYELOMA AND OTHER PLASMA CELL DISEASES

multiplemyelomawos

CURRENT TREATMENT METHODS FOR EARLY RELAPSED MULTIPLE MYELOMA

Buğra Sağlam1 Pınar Tığlıoğlu2

1Medicalpoint Gaziantep Hospital, Department of Hematology, Gaziantep, Türkiye
2İstanbul Medeniyet University, Faculty of Medicine, Department of Hematology, İstanbul, Türkiye

Sağlam B, Tığlıoğlu P. Current Treatment Methods for Early Relapsed Multiple Myeloma. In: Sevindik ÖG, editor. Multiple Myeloma and Other Plasma Cell Diseases. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.55-63.

ABSTRACT

The diagnosis and treatment of multiple myeloma, which is the second most common disease among all hematologic malignancies, has been greatly improved in the last 30 years, and with the ease of access to large patient groups, there have been great improvements in terms of overall survival and progression-free survival. However, despite all these advances, drug resistance, progressive disease under treatment and early nudex still challenge clinicians as an important problem. Although there are various definitions for early nux, a wide time interval such as 12-24 months is taken as a basis in various sources. In individuals with recurrent, progressive disease in such an early period, it naturally leads to recurrent treatment failures and low survival outcomes. Identifying these patients at an early stage and treating them with the most appropriate treatment options remains the most important stage in the management of these patients and the success of long survival.

Keywords: Multiple myeloma; Recurrence; Survival; Drug resistance; Neoplasm

Referanslar

  1. Legarda MA, Cejalvo MJ, de la Rubia J. Recent advances in the treatment of patients with multiple myeloma. Cancers. Nov 30 2020;12(12):3576. [Crossref]  [PubMed]  [PMC]
  2. Jeryczynski G, Bolomsky A, Agis H, Krauth M-T. Stratification for RRMM and risk-adapted therapy: sequencing of therapies in RRMM. Cancers. Nov 23 2021;13(23):5886. [Crossref]  [PubMed]  [PMC]
  3. Dima D, Jiang D, Singh DJ, et al. Multiple myeloma therapy: emerging trends and challenges. Cancers. Aug 23 2022;14(17):4082. [Crossref]  [PubMed]  [PMC]
  4. Nijhof IS, van de Donk NW, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. Jan 2018;78(1):19-37. [Crossref]  [PubMed]  [PMC]
  5. Castelli R, Gualtierotti R, Orofino N, Losurdo A, Gandolfi S, Cugno M. Current and emerging treatment options for patients with relapsed myeloma. Clinical Medicine Insights: Oncology. Aug 19 2013;7:CMO. S8014. [Crossref]  [PubMed]  [PMC]
  6. Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. Jama. Feb 1 2022;327(5):464-477. [Crossref]  [PubMed]
  7. Dimopoulos M-A, Richardson P, Lonial S. Treatment op tions for patients with heavily pretreated relapsed and refractory multiple myeloma. Clinical Lymphoma Myeloma and Leukemia. Jul 2022;22(7):460-473. [Crossref]  [PubMed]
  8. Wang C, Soekojo CY, Mel Sd, et al. Natural history and prognostic factors at first relapse in multiple myeloma. Cancers. Jul 2 2020;12(7):1759. [Crossref]  [PubMed]  [PMC]
  9. Schavgoulidze A, Cazaubiel T, Perrot A, Avet-Loiseau H, Corre J. Multiple myeloma: heterogeneous in every way. Cancers. Mar 13 2021;13(6):1285. [Crossref]  [PubMed]  [PMC]
  10. Gahvari ZJ, Callander NS. The Management of Relapsed and Refractory Multiple Myeloma. Oncology (Williston Park, NY). Apr 25 2023;37(4):164-174. [Crossref]  [PubMed]
  11. Tandon N, Rajkumar S, LaPlant B, et al. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood cancer journal. Feb 17 2017;7(2):e528-e528. [Crossref]  [PubMed]  [PMC]
  12. Liu Y, Wen L, Chen H, et al. Serum lactate dehydrogenase can be used as a factor for re-evaluating first-relapsed multiple myeloma. Acta Haematologica. 2020;143(6):559-566. [Crossref]  [PubMed]
  13. Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. Jan 2020;34(1):1-20. [Crossref]  [PubMed]
  14. Mohyuddin GR, Koehn K, Shune L, et al. Renal insufficiency in multiple myeloma: A systematic review and meta-analysis of all randomized trials from 2005-2019. Leukemia & Lymphoma. Jun 2021;62(6):1386-1395. [Crossref]  [PubMed]
  15. Majithia N, Rajkumar S, Lacy M, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. Nov 2016;30(11):2208-2213. [Crossref]  [PubMed]  [PMC]
  16. Bygrave C, Pawlyn C, Davies F, et al. Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. British journal of haematology. May 2021;193(3):551-555. [Crossref]  [PubMed]  [PMC]
  17. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Elsevier; 2004:867-874. [Crossref]  [PubMed]
  18. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. Sep 2019;33(9):2266-2275. [Crossref]  [PubMed]  [PMC]
  19. Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment'approaches in the era of novel agents. Leukemia. Jan 2012;26(1):73-85. [Crossref]  [PubMed]
  20. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine. Oct 6 2016;375(14):13191331. [Crossref]  [PubMed]
  21. Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. Jul 2020;34(7):1875-1884. [Crossref]  [PubMed]  [PMC]
  22. Dimopoulos M, Oriol A, Nahi H, et al. P05: Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with previously treated multiple myeloma: overall survival results from the phase 3 POLLUX trial. HemaSphere. 2022;6:13. [Crossref]  [PMC]
  23. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. New England Journal of Medicine. Aug 25 2016;375(8):754-766. [Crossref]  [PubMed]
  24. Mateos M-V, Sonneveld P, Hungria V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clinical Lymphoma Myeloma and Leukemia. Aug 2020;20(8):509-518. [Crossref]  [PubMed]
  25. Sonneveld P, Chanan-Khan A, Weisel K, et al. P04: Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone alone in patients with previously treated multiple myeloma: Overall survival results from the phase 3 CASTOR trial. HemaSphere. 2022;6:12. [Crossref]  [PMC]
  26. Dimopoulos M, Quach H, Mateos M-V, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. The Lancet. Jul 18 2020;396(10245):186-197. [Crossref]  [PubMed]
  27. Usmani SZ, Quach H, Mateos M-V, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. The Lancet Oncology. Jan 2022;23(1):65-76. [Crossref]  [PubMed]
  28. Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. The Lancet Oncology. Jun 2021;22(6):801812.
  29. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. New England Journal of Medicine. Jan 8 2015;372(2):142-152. [Crossref]  [PubMed]
  30. Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology. Mar 10 2018;36(8):728-734. [Crossref]  [PubMed]
  31. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. New England Journal of Medicine. Aug 13 2015;373(7):621-631. [Crossref]  [PubMed]
  32. Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood cancer journal. Sep 4 2020;10(9):91. [Crossref]  [PubMed]  [PMC]
  33. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. The Lancet. Dec 7 2019;394(10214):2096-2107.
  34. Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. The Lancet Oncology. Mar 2022;23(3):416-427. [Crossref]  [PubMed]
  35. Moreau P, Dimopoulos M-A, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. The Lancet. Jun 19 2021;397(10292):2361-2371.
  36. Moreau P, Dimopoulos M, Mikhael J, et al. VP5-2022: updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM). Annals of Oncology. 2022;33(6):664-665. [Crossref]
  37. Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. The Lancet Oncology. Jun 2019;20(6):781794.
  38. Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twiceper-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. The Lancet. Nov 14 2020;396(10262):1563-1573. [Crossref]  [PubMed]
  39. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine. Apr 28 2016;374(17):16211634. [Crossref]  [PubMed]
  40. Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology. Aug 1 2021;39(22):2430-2442. [Crossref]  [PubMed]
  41. Harrison SJ, Perrot A, Alegre A, et al. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. British Journal of Haematology. Jul 2021;194(1):120-131. [Crossref]  [PubMed]  [PMC]
  42. Richard S, Chari A, Delimpasi S, et al. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. American Journal of Hematology. Sep 1 2021;96(9):1120-1130.
  43. Walker CJ, Li S, Chai Y, et al. Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM). Wolters Kluwer Health; 2021. [Crossref]
  44. Kaufman JL, Gasparetto C, Schjesvold FH, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t (11; 14) multiple myeloma. American journal of hematology. Apr 1 2021;96(4):418-427. [Crossref]  [PubMed]  [PMC]
  45. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. New England Journal of Medicine. Apr 6 2017;376(14):1311-1320. [Crossref]  [PubMed]  [PMC]
  46. Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. New England Journal of Medicine. Jul 14 2022;387(2):132-147.
  47. Giralt S, Garderet L, Durie B, et al. American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and international myeloma working group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biology of Blood and Marrow Transplantation. Dec 2015;21(12):2039-2051.
  48. Vij R, Kumar S, Zhang M-J, et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation. Feb 2015;21(2):335-341. [Crossref]  [PubMed]  [PMC]
  49. Miller KC, Gertz MA, Buadi FK, et al. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone marrow transplantation. Dec 2019;54(12):2039-2050. [Crossref]  [PubMed]  [PMC]
  50. Veltri LW, Milton DR, Delgado R, et al. Outcome of autol ogous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. Sep 15 2017;123(18):3568-3575. [Crossref]  [PubMed]  [PMC]